LBIO Lion Biotechnologies Inc

Iovance Biotherapeutics to Present at Two Investor Conferences in September

Iovance Biotherapeutics to Present at Two Investor Conferences in September

SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in September:

  • 2018 H.C. Wainwright Annual Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at 10:50 a.m. ET

     
  • Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m. ET  

A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at . A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit .

Investor Relations Contact:

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200



Media Contact:

John Capodanno

FTI Consulting

212-850-5705



EN
29/08/2018

Underlying

LBIOLion Biotechnologies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lion Biotechnologies Inc

 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: TD Cowen 46th Annual Healthcare Conference Presentation: March 2, 2026 at 9:50 a.m. ETBoston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat: March 11, 2026 ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Announces Positive Results from the First Clinical Trial for T...

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a led by ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year...

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance’s common stock to two new, non-executive ...

February 20, 2026 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Fi...

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates. To list...

February 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch